Prof Philippe Moreau, Prof Pieter Sonneveld and Prof Hartmut Goldschimdt come together for ecancertv at IMW 2013. High-dose therapy (HDT) with autologous stem cell transplant (ASCT) for multiple myeloma (MM) has been considered the standard of care for frontline treatment in younger patients with adequate organ function.
The introduction of novel agents, specifically thalidomide, bortezomib and lenalidomide, has changed the ASCT scenario in several ways.
Novel agents are now being incorporated as part of induction therapy and have been investigated for use on consolidation and maintenance post-ASCT.
The overall goal remains progression free survival and overall survival.
The efficacy of novel agents has led to the investigation of these agents upfront without ASCT, leading to much debate regarding the positioning of ASCT in the treatment of MM.
The role of allogeneic transplantation has been investigated in MM patients, and it may have a role in the treatment of high risk young patients or patients in first relapse.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).